Cancer biology overlaps frequently, and some drugs designed for a specific mutation may have multiple uses, as one study shows.

Non-small cell lung cancer ( NSCLC ) is a tough one, but r esearchers have found a new target for treating this disease. When added to other therapies, the combination might just deliver a knock-out punch.

In the not too distant future, sophisticated genetic screening may be done on a routine basis in a hospital lab. And this means cancer patients increasingly will be treated with therapies that target their specific genetic needs.

Detroit is known as the 'Motor City,' 'Motown' or 'Hockeytown.' It may soon get another unfortunate distinction when it comes to lung cancer.

Once lung cancer moves beyond its original site, the prognosis dims. Researchers have discovered that a specific test can be used to identify patients who will benefit from different types of therapy - a finding that offers more personalized care for advanced lung cancer patients.

Radiation oncologists believed that a higher dosage of radiation would extend the lives of patients with advanced lung cancer. It seemed logical, but the findings of a clinical trial don't support that logic.

Days after receiving U.S. Food and Drug Administration (FDA) approval, the Abbott ALK test for non-small-cell lung cancer (NSCLC) has become available in the United States, European Union and New Zealand.

Being diagnosed with lung cancer usually means months of chemotherapy followed by a relapse. That outlook is changing for the better.

Advanced lung cancer offers few options for patients, unfortunately. A recent Spanish study opens new possibilities by extending the use of an established treatment drug, Alimta.

While smokers are the largest group of people diagnosed with lung cancer, surpirsingly individuals who have never smoked tobacco make up one quarter of all victims.